Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $18.6200 (-1.06%) ($18.5800 - $19.3700) on Fri. Jun. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.36% (three month average) | RSI | 51 | Latest Price | $18.6200(-1.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.68% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-3%) XLC(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.68% (StdDev 7.36%) | Hourly BBV | 0 () | Intraday Trend | -2.3% | | | |
|
5 Day Moving Average | $18.38(1.31%) | 10 Day Moving Average | $17.99(3.5%) | 20 Day Moving Average | $18.54(0.43%) | To recent high | -14.7% | To recent low | 146.9% | Market Cap | $2.358b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |